We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Allergy Therapeutics

News List

Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate pharmatimes
January 07, 2021
Allergy Therapeutics has initiated a biomarker study at Imperial College London, which will aim to evaluate its novel virus like particle (VLP) based peanut allergy vaccine candidate.
Positive Phase I results for Allergy’s Acarovac pharmatimes
May 21, 2019
Allergy Therapeutics announced positive Phase I safety and tolerability results of its subcutaneous Acarovac MPL (Monophosphoryl Lipid A). The results were in patients with house dust mite-induced allergic rhinoconjunctivitis.
Allergy Therapeutics’ birch pollen product fails to meet primary endpoint pharmaceutical-technology
March 20, 2019
UK-based Allergy Therapeutics has announced that its new adjuvanted allergoid product indicated for birch pollen-induced seasonal allergic rhinitis failed to meet the primary endpoint in the Phase III B301 trial.
Setback for Allergy’s birch pollen immunotherapy drugs
March 19, 2019
Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.